Immpact Bio USA Inc. has obtained IND clearance from the FDA for IMPT-514, a CD19/CD20 bispecific chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with multiple sclerosis (MS). A phase I trial will focus on patients who have suboptimal disease control despite prior treatment with high efficacy disease-modifying therapies in all forms of MS.
Cycloicaritin (CICT) is a bioactive natural flavonoid extracted from Epimedium species with anti-inflammatory, antimicrobial or antiproliferative effects but with low bioavailability.
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the main causes of both community-acquired and hospital-acquired infections and has become resistant to almost all known available antibiotics. Researchers from Hong Kong Polytechnic University and collaborators reported on a new series of indole-benzosulfonamide oleanolic acid derivatives with the potential to be used against multidrug-resistant bacteria.
The gastrointestinal tract could be key to developing new drugs to combat resistant bacteria. Computational analysis of the human microbiome has revealed a new class of peptides with antimicrobial potential that, once synthesized, inhibited the growth of several microorganisms in vitro and in vivo.
After sparking further interest from investors after the close of its series A, Vandria SA has extended the round and now has the means to advance its lead mitophagy inducer program as far as phase Ib/IIa development in the treatment of mild cognitive impairment.
Opna Bio AG has described transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of arrhythmogenic right ventricular cardiomyopathy, cancer, Holt-Oram syndrome, neurofibromatosis type 2, polycystic kidney disease and Alzheimer’s disease.
Enliven Therapeutics Inc. has divulged Raf kinase inhibitors reported to be useful for the treatment of cancer. An exemplified compound (Ex 5 [isomer B] pg 130) inhibited ERK phosphorylation in human melanoma A-375 cells (IC50=12.4 nM) in ELISA assays.
Researchers at De Montfort University and Loughborough University have identified trifluoroquinazolines acting as lysyl tRNA synthetase (KARS) inhibitors reported to be useful for the treatment of parasitic infections.
RSS
